More Patents, Less Signal: Why a Bigger Drug Patent Database Can Give You Worse Intelligence
I-MAK counts 257 U.S. patent applications and 130 granted U.S. patents on Humira (adalimumab) [1]. In its 2016 BPCIA suit
Delisted Drug Patents: Six Ways a Patent Leaves the Orange Book, and What Each Exit Changes
On December 10, 2025, Teva asked FDA to remove more than 200 patent listings from the Orange Book. [1] The
From Patent Cliff to Partnership Pipeline: A 7-Step Framework Built on 2026 Deal Data
Biopharma companies announced $130 billion of acquisitions in the first half of 2026. That is about 98% of the $133
From Patent Cliff to Partnership Pipeline: A 7-Step Framework Built on 2026 Deal Data Read Post »
Drug Patent Portfolios More Than Tripled Since 1990. Here Is What Changed
A small-molecule drug approved in 1990 had 2.1 FDA-listed patents on average. A drug approved in 2019 had 6.9 [1].
Drug Patent Portfolios More Than Tripled Since 1990. Here Is What Changed Read Post »
Grading the Lifecycle Playbook: What Keytruda, Stelara, and Eliquis Reveal About Patent-Cliff Strategy
Johnson & Johnson’s Stelara sales fell 59.7% year over year in the first quarter of 2026, to $656 million, after
Drug Patent Abandonment, Decoded: The 2026 Revival-Rule Change, the 33% Figure, and What It Means for Generic Entry
On August 13, 2026, the rules governing “zombie patent” revivals get tighter. The U.S. Patent and Trademark Office finalized a
Drug Naming Now Costs $28,000 a Word: Inside the USAN, INN, and FDA System That Decides What Every Medicine Is Called
In September 2025, the FDA sent more than 50 warning letters to compounding pharmacies and telehealth sellers of semaglutide and
The -Mab Suffix Is Dying. Here’s the Naming System Replacing It
In October 2021, the WHO’s INN Expert Group voted to retire the single most recognizable suffix in pharmaceutical nomenclature. Every
The -Mab Suffix Is Dying. Here’s the Naming System Replacing It Read Post »
The AB Rating Is the Whole Business Model: Why America’s Branded Generics Live or Die on One Orange Book Letter
In November 2014, the FDA changed two letters next to a drug’s name in a government database, and a $1.23
